Gilead Sciences EBITDA 2010-2022 | GILD

Gilead Sciences annual and quarterly EBITDA history from 2010 to 2022. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Gilead Sciences EBITDA for the quarter ending March 31, 2022 was $0.722B, a 78.53% decline year-over-year.
  • Gilead Sciences EBITDA for the twelve months ending March 31, 2022 was $9.327B, a 51.34% increase year-over-year.
  • Gilead Sciences 2021 annual EBITDA was $11.968B, a 115.6% increase from 2020.
  • Gilead Sciences 2020 annual EBITDA was $5.551B, a 2.46% decline from 2019.
  • Gilead Sciences 2019 annual EBITDA was $5.691B, a 40.9% decline from 2018.
Gilead Sciences Annual EBITDA
(Millions of US $)
2021 $11,968
2020 $5,551
2019 $5,691
2018 $9,629
2017 $15,410
2016 $18,791
2015 $23,291
2014 $16,315
2013 $4,869
2012 $4,288
2011 $4,092
2010 $4,228
2009 $3,742
Gilead Sciences Quarterly EBITDA
(Millions of US $)
2022-03-31 $722
2021-12-31 $1,475
2021-09-30 $4,365
2021-06-30 $2,765
2021-03-31 $3,363
2020-12-31 $3,078
2020-09-30 $2,356
2020-06-30 $-2,634
2020-03-31 $2,751
2019-12-31 $1,443
2019-09-30 $-1,126
2019-06-30 $2,778
2019-03-31 $2,596
2018-12-31 $1,502
2018-09-30 $2,981
2018-06-30 $2,636
2018-03-31 $2,510
2017-12-31 $2,688
2017-09-30 $4,109
2017-06-30 $4,552
2017-03-31 $4,061
2016-12-31 $4,337
2016-09-30 $4,698
2016-06-30 $4,822
2016-03-31 $4,934
2015-12-31 $5,899
2015-09-30 $5,863
2015-06-30 $5,889
2015-03-31 $5,640
2014-12-31 $4,605
2014-09-30 $3,748
2014-06-30 $4,678
2014-03-31 $3,284
2013-12-31 $1,325
2013-09-30 $1,217
2013-06-30 $1,227
2013-03-31 $1,100
2012-12-31 $1,180
2012-09-30 $1,115
2012-06-30 $1,127
2012-03-31 $866
2011-12-31 $941
2011-09-30 $1,077
2011-06-30 $1,092
2011-03-31 $983
2010-12-31 $907
2010-09-30 $1,048
2010-06-30 $1,051
2010-03-31 $1,221
2009-12-31 $1,130
2009-09-30 $951
2009-06-30 $814
2009-03-31 $847
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $80.075B $27.305B
Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00